Overview

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A Phase II Study of Nivolumab in Patients with Genetic alterations in DNA Damage repair and response Who Progressed after Standard treatment for Metastatic Solid Cancers

Phase:

Phase 2

Details

Lead Sponsor:

Korean Cancer Study Group

Treatments:

Nivolumab